PYC 002
Alternative Names: PYC-002Latest Information Update: 11 Dec 2023
At a glance
- Originator PYC Therapeutics
- Class Antisense oligonucleotides; Morpholines; Peptide drug conjugates
- Mechanism of Action RNA interference; SHANK3 protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Telomeric 22q13 Monosomy Syndrome
Most Recent Events
- 11 Dec 2023 Preclinical trials in Telomeric 22q13 Monosomy Syndrome in Australia (Parenteral) (PYC Therapeutics pipeline, December 2023)
- 21 Jul 2023 Early research in Telomeric 22q13 Monosomy Syndrome in Australia (Parenteral), before July 2023 (PYC Therapeutics pipeline, July 2023)